CR8302A - Compuestos heterociclicos fusionados - Google Patents

Compuestos heterociclicos fusionados

Info

Publication number
CR8302A
CR8302A CR8302A CR8302A CR8302A CR 8302 A CR8302 A CR 8302A CR 8302 A CR8302 A CR 8302A CR 8302 A CR8302 A CR 8302A CR 8302 A CR8302 A CR 8302A
Authority
CR
Costa Rica
Prior art keywords
fusioned
heterociclic compounds
heterociclic
compounds
seratonin
Prior art date
Application number
CR8302A
Other languages
English (en)
Spanish (es)
Inventor
Mani Neelakandha
I Carruthers Nicholas
Chai Wenying
Deng Xiaohu
A Dvorak Curt
K Kwok Annette
A Rudolph Dale
D Wong Victoria
T Liang Jimmy
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34526458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8302(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR8302A publication Critical patent/CR8302A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CR8302A 2003-09-17 2006-03-17 Compuestos heterociclicos fusionados CR8302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50452803P 2003-09-17 2003-09-17
US55267304P 2004-03-11 2004-03-11

Publications (1)

Publication Number Publication Date
CR8302A true CR8302A (es) 2008-09-10

Family

ID=34526458

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8302A CR8302A (es) 2003-09-17 2006-03-17 Compuestos heterociclicos fusionados

Country Status (29)

Country Link
US (5) US7402680B2 (cg-RX-API-DMAC10.html)
EP (1) EP1668014B1 (cg-RX-API-DMAC10.html)
JP (1) JP5069907B2 (cg-RX-API-DMAC10.html)
KR (1) KR101151653B1 (cg-RX-API-DMAC10.html)
CN (1) CN103788089A (cg-RX-API-DMAC10.html)
AR (1) AR047218A1 (cg-RX-API-DMAC10.html)
AT (1) ATE420881T1 (cg-RX-API-DMAC10.html)
AU (1) AU2004283196B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0414541B8 (cg-RX-API-DMAC10.html)
CA (1) CA2539426C (cg-RX-API-DMAC10.html)
CL (1) CL2009000943A1 (cg-RX-API-DMAC10.html)
CR (1) CR8302A (cg-RX-API-DMAC10.html)
CY (1) CY1109416T1 (cg-RX-API-DMAC10.html)
DE (1) DE602004019118D1 (cg-RX-API-DMAC10.html)
DK (1) DK1668014T3 (cg-RX-API-DMAC10.html)
EA (2) EA200801812A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP066436A (cg-RX-API-DMAC10.html)
ES (1) ES2319539T3 (cg-RX-API-DMAC10.html)
IL (2) IL174283A (cg-RX-API-DMAC10.html)
IS (1) IS2756B (cg-RX-API-DMAC10.html)
MX (1) MXPA06003150A (cg-RX-API-DMAC10.html)
NI (1) NI200600094A (cg-RX-API-DMAC10.html)
NZ (1) NZ545836A (cg-RX-API-DMAC10.html)
PL (1) PL1668014T3 (cg-RX-API-DMAC10.html)
PT (1) PT1668014E (cg-RX-API-DMAC10.html)
SG (1) SG146683A1 (cg-RX-API-DMAC10.html)
SI (1) SI1668014T1 (cg-RX-API-DMAC10.html)
TW (1) TWI345565B (cg-RX-API-DMAC10.html)
WO (1) WO2005040169A2 (cg-RX-API-DMAC10.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG146683A1 (en) * 2003-09-17 2008-10-30 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
CA2557158A1 (en) * 2004-02-20 2005-09-01 Astellas Pharma Inc. Prophylactic antimigraine agents
KR101216984B1 (ko) * 2004-06-30 2013-01-02 아더시스 인코포레이티드 세로토닌 수용체 조절자로서의 치환된 아제핀 유도체
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080171788A1 (en) * 2005-02-08 2008-07-17 Shinobu Akuzawa Medicament For Irritable Bowel Syndrome
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GB0513886D0 (en) * 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP1928461B1 (en) * 2005-08-04 2012-01-04 Janssen Pharmaceutica NV Pyrimidine compounds as serotonin receptor modulators
EP1923387B1 (en) * 2005-08-08 2011-10-19 Astellas Pharma Inc. Acylguanidine derivative or salt thereof
EP1981337B1 (en) 2006-01-19 2015-09-02 Athersys, Inc. Thiophenyl azepines as serotonin 5-ht2c receptor ligands and uses thereof
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
CN101479252B (zh) * 2006-05-05 2014-01-29 詹森药业有限公司 用于制备含吡唑的化合物的方法
ATE458740T1 (de) * 2006-08-28 2010-03-15 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
WO2009058810A1 (en) * 2007-11-02 2009-05-07 Janssen Pharmaceutica N.V. Process for the preparation of substituted 2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene derivatives
WO2009085847A1 (en) * 2008-01-03 2009-07-09 Allergan, Inc. Tetrahydroindoles having sphingosine-1-phosphate receptor activity
WO2010053825A1 (en) 2008-10-29 2010-05-14 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
PE20110590A1 (es) 2008-11-18 2011-08-31 Hoffmann La Roche Alquilciclohexileteres de dihidrotetraazabenzoazulenos
US8309578B2 (en) * 2008-11-25 2012-11-13 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
TWI410418B (zh) * 2009-04-29 2013-10-01 Ind Tech Res Inst 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
AU2012244846B2 (en) 2011-04-21 2016-07-07 Basf Se Novel pesticidal pyrazole compounds
CN103889983B (zh) 2011-09-14 2015-12-09 普罗克西梅根有限公司 酶抑制剂化合物
WO2013156318A1 (en) 2012-04-16 2013-10-24 Basf Se Substituted pesticidal pyrazole compounds
BR122019015109B1 (pt) 2012-06-20 2020-04-07 Basf Se mistura pesticida, composição, composição agrícola, métodos para o combate ou controle das pragas de invertebrados, para a proteção dos vegetais em crescimento ou dos materias de propagação vegetal, para a proteção de material de propagação vegetal e uso de uma mistura pesticida
PE20151139A1 (es) * 2012-08-16 2015-08-07 Janssen Pharmaceutica Nv Pirrolopirazoles como bloqueadores del canal de calcio tipo n
WO2014063942A1 (en) 2012-10-23 2014-05-01 Basf Se Substituted pesticidal pyrazole compounds
WO2014100815A2 (en) 2012-12-21 2014-06-26 Abt Holding Company Benzazepines as serotonin 5-ht2c receptor ligands and uses thereof
US9309262B2 (en) 2013-03-13 2016-04-12 Abt Holding Company Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2015055497A1 (en) 2013-10-16 2015-04-23 Basf Se Substituted pesticidal pyrazole compounds
CA2968434A1 (en) * 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
CA2975997A1 (en) * 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
CN105503647A (zh) * 2015-12-10 2016-04-20 苏州昊帆生物科技有限公司 环丙基肼盐酸盐的制备方法
WO2017175045A1 (en) * 2016-04-08 2017-10-12 The Hong Kong Polytechnic University Pyrimidines for treatment of bacterial infections
KR101917264B1 (ko) 2016-12-22 2018-11-13 한국과학기술연구원 5-ht7 수용체 조절제로 작용하는 아제핀 유도체
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
WO2019137995A1 (en) 2018-01-11 2019-07-18 Basf Se Novel pyridazine compounds for controlling invertebrate pests
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
WO2021145655A1 (ko) * 2020-01-13 2021-07-22 압타바이오 주식회사 신규한 피라졸 유도체
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
WO2022052958A1 (en) 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN119998295A (zh) 2022-06-08 2025-05-13 因赛特公司 作为dgk抑制剂的三环三唑并化合物
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197466B (de) * 1962-03-22 1965-07-29 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen
US3312716A (en) * 1964-08-11 1967-04-04 Aldrich Chem Co Inc 4-hydroxy-3-pyrrolidinemethanols
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1484140A (en) * 1974-04-24 1977-08-24 Wyeth John & Brother Ltd Pyrrolopyridine derivatives
US3969355A (en) * 1974-11-01 1976-07-13 Morton-Norwich Products, Inc. 5-Aminoethyl-2,4-diphenylpyrimidine dihydrobromide
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK27383A (da) 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4857330A (en) * 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
JPH03148265A (ja) 1989-11-01 1991-06-25 Sumitomo Chem Co Ltd ５，７―ジフェニル―４，６―ジアザインダン誘導体、その製造法およびそれを有効成分とする除草剤
US5137890A (en) * 1990-02-14 1992-08-11 Ortho Pharmaceutical Corporation 4-phenyl tetrahydropyrido(4,3-d)pyrimidines
US5053508A (en) 1990-03-09 1991-10-01 American Home Products Corporation Fused heterotricyclic imides with psychotropic activity and intermedrates thereof
US5648352A (en) * 1991-09-13 1997-07-15 Merck & Co., Inc. Piperazinylcamphorsulfonyl oxytocin antagonists
EP0638071B1 (en) 1992-12-28 1997-04-09 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
US6677310B1 (en) * 1999-04-21 2004-01-13 Nabi Ring-expanded nucleosides and nucleotides
US5843912A (en) * 1994-07-06 1998-12-01 Universy Of Maryland Ring-expanded nucleosides and nucleotides
US5405848A (en) * 1993-12-22 1995-04-11 Ortho Pharmaceutical Corporation Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors
US5663178A (en) * 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
ES2223049T3 (es) 1994-04-29 2005-02-16 Pfizer Inc. Amidas aciclicas y ciclicas novedosas como estimuladores de la liberacion de neurotransmisores.
WO1996032944A1 (en) 1995-04-18 1996-10-24 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
JP2000504677A (ja) 1996-02-09 2000-04-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ７レセプター・アンタゴニスト用のスルホンアミド誘導体
TW470745B (en) * 1996-05-23 2002-01-01 Janssen Pharmaceutica Nv Hexahydro-pyrido[4,3-b]indole derivatives
WO1997047601A1 (en) 1996-06-11 1997-12-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
EP0912550A1 (en) 1996-06-25 1999-05-06 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
WO1998000400A1 (en) 1996-06-28 1998-01-08 Meiji Seika Kaisha, Ltd. Tetrahydrobenzindole compounds
GB9700899D0 (en) 1997-01-17 1997-03-05 Smithkline Beecham Plc Novel treatment
US6177443B1 (en) * 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
EP0973778A1 (en) 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
EP0905136A1 (en) 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
US5951518A (en) 1997-10-31 1999-09-14 Teleflex, Incorporated Introducing device with flared sheath end
WO1999024022A2 (en) 1997-11-10 1999-05-20 F. Hoffmann-La Roche Ag Isoquinoline derivatives for treating disorders associated with 5ht7 receptors
US6407112B1 (en) * 1998-04-22 2002-06-18 Meiji Seika Kaisha, Ltd. Optically active tetrahydrobenzindole derivative
HK1040055B (zh) 1998-05-22 2005-04-01 伊莱利利公司 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
AU1321900A (en) 1998-10-23 2000-05-15 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6245785B1 (en) 1998-11-30 2001-06-12 Warner Lambert Company Dissolution of triprolidine hydrochloride
GB9828004D0 (en) 1998-12-18 1999-02-10 Smithkline Beecham Plc Use
GB9906624D0 (en) 1999-03-23 1999-05-19 Smithkline Beecham Plc Novel compounds
PL350884A1 (en) 1999-04-01 2003-02-10 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
DE60008550T2 (de) 1999-09-09 2004-08-05 Kumiai Chemical Industry Co., Ltd. Pyrimidinderivate und herbizide welche diese enthalten
WO2001029029A1 (en) 1999-10-18 2001-04-26 Smithkline Beecham P.L.C. Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
JP2003522178A (ja) 2000-02-04 2003-07-22 ワイス ピロロイソキノリンおよびテトラヒドロピロロイソキノリン誘導体ならびに５−ｈｔ７受容体の媒介物質としてのそれらの使用
US20040087798A1 (en) 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
US6586469B2 (en) 2000-07-25 2003-07-01 Medpointe Healthcare Inc. Antihistaminic/antitussive compositions
US7589202B2 (en) 2000-08-14 2009-09-15 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
JP2004531456A (ja) * 2000-09-06 2004-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾールを用いてアレルギーを治療する方法
US20040267010A1 (en) 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
HUP0303270A3 (en) * 2001-02-21 2007-03-28 Janssen Pharmaceutica Nv Isoxazoline derivatives as anti-depressants, process for their preparation and pharmaceutical compositions containing them
US20020183519A1 (en) * 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
DE10111842A1 (de) 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
US6559174B2 (en) * 2001-03-20 2003-05-06 Merck & Co., Inc. N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
US6806380B2 (en) * 2001-10-02 2004-10-19 Lexicon Pharmaceuticals, Inc. Modified safe and efficient process for the environmentally friendly synthesis of imidoesters
IL161576A0 (en) * 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
US20030199542A1 (en) * 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
US20030199544A1 (en) * 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
HRP20020452A2 (en) 2002-05-23 2004-02-29 Pliva D D 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof
CA2487679A1 (en) * 2002-05-30 2003-12-11 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases
AU2003240434A1 (en) * 2002-06-20 2004-01-06 H. Lundbeck A/S Combination therapy wherein a serotinin reuptake inhibitor is used
MXPA05000945A (es) 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
US20060100233A1 (en) * 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JPWO2004011467A1 (ja) 2002-07-29 2005-12-15 北興化学工業株式会社 トリアゾロピリミジン誘導体および農園芸用殺菌剤
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
EP1556360B1 (en) 2002-10-30 2008-01-23 Ciba SC Holding AG Electroluminescent device
CA2514656A1 (en) * 2003-01-31 2004-08-12 Pfizer Products Inc. 5ht7 antagonists and inverse agonists
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
GB0316128D0 (en) 2003-07-10 2003-08-13 Univ Aston Novel sulfonamide compounds
WO2005009387A2 (en) 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
SG146683A1 (en) * 2003-09-17 2008-10-30 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
JP2007517766A (ja) 2003-09-24 2007-07-05 コンビナトアールエックス インコーポレーティッド 薬物の組み合わせを投与するための治療法
WO2005056056A2 (en) 2003-12-15 2005-06-23 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20090227562A1 (en) 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
US20060037652A1 (en) 2004-08-23 2006-02-23 Ranco Incorporated Of Delaware Reversing valve assembly with improved pilot valve mounting structure
CN101128432A (zh) * 2004-12-17 2008-02-20 詹森药业有限公司 用于治疗中枢神经系统疾病的四氢异喹啉化合物
AU2006259257A1 (en) * 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Hexahydro-pyrrolo-isoquinoline compounds for the treatment of CNS disorders
AU2006261162A1 (en) * 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Naphthyridine compounds
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP1928461B1 (en) 2005-08-04 2012-01-04 Janssen Pharmaceutica NV Pyrimidine compounds as serotonin receptor modulators
WO2007106349A2 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
CN101479252B (zh) * 2006-05-05 2014-01-29 詹森药业有限公司 用于制备含吡唑的化合物的方法
EP2049473A2 (en) * 2006-06-29 2009-04-22 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
JP2009542708A (ja) * 2006-06-29 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換アミノメチルベンズアミド化合物
AU2007265239A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Butyl and butynyl benzyl amine compounds
US20080139564A1 (en) * 2006-11-16 2008-06-12 Keith John M Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators

Also Published As

Publication number Publication date
AU2004283196A1 (en) 2005-05-06
US7402680B2 (en) 2008-07-22
US20110040088A1 (en) 2011-02-17
US20100016281A1 (en) 2010-01-21
PL1668014T3 (pl) 2009-06-30
TWI345565B (en) 2011-07-21
EA010905B1 (ru) 2008-12-30
NZ545836A (en) 2009-09-25
EA200600433A1 (ru) 2006-08-25
EP1668014B1 (en) 2009-01-14
JP2007505908A (ja) 2007-03-15
ATE420881T1 (de) 2009-01-15
IS8348A (is) 2006-03-09
CA2539426A1 (en) 2005-05-06
CY1109416T1 (el) 2014-08-13
US8618288B2 (en) 2013-12-31
BRPI0414541B8 (pt) 2021-05-25
EA200801812A1 (ru) 2009-06-30
BRPI0414541A (pt) 2006-11-07
JP5069907B2 (ja) 2012-11-07
ECSP066436A (es) 2006-09-18
US7579470B2 (en) 2009-08-25
CN103788089A (zh) 2014-05-14
WO2005040169A3 (en) 2006-03-30
WO2005040169A2 (en) 2005-05-06
PT1668014E (pt) 2009-03-17
IL174283A0 (en) 2006-08-01
DK1668014T3 (da) 2009-04-20
US20050119295A1 (en) 2005-06-02
EP1668014A2 (en) 2006-06-14
US20090270370A1 (en) 2009-10-29
US7897771B2 (en) 2011-03-01
IL174283A (en) 2012-06-28
CL2009000943A1 (es) 2009-08-21
SI1668014T1 (sl) 2009-06-30
AU2004283196B2 (en) 2011-08-25
NI200600094A (es) 2014-02-25
SG146683A1 (en) 2008-10-30
ES2319539T3 (es) 2009-05-08
CA2539426C (en) 2012-07-10
IS2756B (is) 2011-10-15
BRPI0414541B1 (pt) 2019-02-26
DE602004019118D1 (de) 2009-03-05
BRPI0414541A8 (pt) 2019-01-02
KR101151653B1 (ko) 2012-06-28
US20080103132A1 (en) 2008-05-01
AR047218A1 (es) 2006-01-11
MXPA06003150A (es) 2006-08-31
IL209082A0 (en) 2011-01-31
HK1118550A1 (en) 2009-02-13
KR20070023633A (ko) 2007-02-28
TW200521123A (en) 2005-07-01

Similar Documents

Publication Publication Date Title
NI200600094A (es) Compuesto heterociclicos fusionados
NO2022001I1 (no) Pazopanib
ATE403657T1 (de) Chemische verbindungen
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
ECSP066549A (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
CR8744A (es) Compuestos terapeuticos
BRPI0413449A (pt) compostos de quinoxalina
BRPI0414599A (pt) pirrol-indóis substituìdos
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
ATE409188T1 (de) Naphthyridinverbindungen
SE0301650D0 (sv) Novel compounds
UY28049A1 (es) Derivados de (6,7-dihidro-5h-imidazo(1,2-a) imidazol-3-sulfonilamino)-propionamida
UA85563C2 (ru) Конденсированные гетероциклические соединения
AR032548A1 (es) Metodo y composicion para desinfectar una superficie contaminada con una proteina prion
ECSP056057A (es) Compuestos de benzo[1,2,5]tiadiazole
BRPI0415355A (pt) triarilimidazóis
ATE404550T1 (de) Chemische verbindungen
DE60106947D1 (de) Oxindolderivate
ATE437846T1 (de) Cyclooct-(en-)yl-derivate zur verwendung als duftstoffe
NO20061624L (no) Sammensmeltede heterosykliske forbindelser
MY145145A (en) Fused pyrazole-containing heterocyclic compounds as serotonin receptor modulators
UY28599A1 (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos